Until the beginning of the 90′s, it was commonly thought that adult-onset Growth Hormone Deficiency (GHD) did not bear any clinical relevance. Since then, several studies have systematically investigated GHD syndrome and delineated its association not only with reduced quality of life (QoL), but also with neuropsychiatric-cognitive, cardiovascular, neuromuscular, metabolic, and skeletal disorders, and overall with premature mortality [1]. As a consequence, today Growth Hormone (GH) replacement therapy is recommended to reverse most of these abnormalities with a consistent improvement of QoL.
